Kailera reports Phase 3 China data showing up to 10.9% weight loss with oral GLP-1 drug KAI-7535

Kailera Therapeutics, Inc.

Kailera Therapeutics, Inc.

KLRA

0.00
  • Kailera reported positive topline Phase 3 results in China for oral GLP-1 agonist HRS-7535, also known as KAI-7535.
  • Obesity trial met its primary endpoint, showing up to 10.9% mean weight loss at Week 44, rising to 11.1% at Week 50.
  • Type 2 diabetes trial met its primary endpoint, cutting HbA1c by 1.5% to 1.68% across doses at Week 32.
  • No liver safety signal reported in either trial; gastrointestinal side effects were the most common adverse events.
  • Kailera’s global Phase 2 obesity study started in April 2026; data expected in 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kailera Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607070700PRIMZONEFULLFEED9758095) on July 07, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.